Novo Nordisk (NYSE:NVO) raised its full-year 2026 financial outlook after reporting stronger-than-expected third-quarter sales and adjusted operating profit, supported by continued demand for its obesity treatments in the United States and international markets.
The Danish pharmaceutical company reported adjusted sales of 79.20 billion Danish crowns, up from 74.98 billion crowns a year earlier, while adjusted operating profit increased 27% at constant exchange rates to 31.72 billion crowns.
Obesity care revenue climbed 22% at constant exchange rates to 26.15 billion crowns, reflecting higher treatment volumes across key markets.
Following the results, Novo Nordisk improved its full-year guidance for adjusted sales and adjusted operating profit, while also substantially increasing its free cash flow forecast.
Novo Nordisk revised its financial expectations for 2026 following stronger-than-anticipated performance during the third quarter.
The company now expects adjusted sales and adjusted operating profit to range between a 2% decline and 2% growth at constant exchange rates.
Its previous guidance anticipated a decline of between 6% and 0% for both measures.
The revised outlook represents an improvement of four percentage points at both ends of the guidance range, reflecting stronger operating performance and continued demand for the company’s pharmaceutical products.
The midpoint of the new forecast is unchanged year over year, compared with a 3% decline under the previous guidance.
The upgrade suggests that management expects a more stable financial performance for the full year than previously anticipated.
Demand for obesity treatments remains an important contributor to the company’s revenue, although pricing developments and operating costs continue to influence profitability.
Novo Nordisk reported third-quarter adjusted sales of 79.20 billion Danish crowns, compared with 74.98 billion crowns in the corresponding period of 2025.
The result exceeded the Visible Alpha analyst consensus of 73.4 billion crowns by approximately 8%.
The stronger-than-expected performance reflected continued demand across the company’s pharmaceutical portfolio, particularly in obesity care.
Adjusted operating profit increased 27% at constant exchange rates to 31.72 billion crowns, compared with 23.68 billion crowns a year earlier.
The figure was approximately 10% above the analyst consensus estimate of 28.9 billion crowns.
The results demonstrated stronger underlying profitability despite challenges associated with restructuring expenses and asset impairments.
However, the difference between adjusted and reported earnings was substantial, reflecting significant non-cash charges recognised during the quarter.
Although adjusted operating profit increased significantly, Novo Nordisk reported a decline in operating profit on a statutory basis.
Reported operating profit fell 9% at constant exchange rates to 23.01 billion crowns.
The decrease reflected non-cash impairment charges totalling 8.7 billion crowns.
Of this amount, 4.6 billion crowns related to a write-down associated with ziltivekimab, while another 4.1 billion crowns was linked to the restructuring of the company’s manufacturing network.
Impairment charges are accounting adjustments that reduce the carrying value of assets when their recoverable value is assessed to be lower than previously recorded.
Although these charges reduced reported profitability, they did not represent equivalent cash outflows during the quarter.
The distinction between reported and adjusted operating profit was therefore important in assessing Novo Nordisk’s underlying financial performance.
The company continued to generate growth in adjusted earnings despite the substantial impact of these accounting adjustments.
Novo Nordisk’s obesity care business remained a major contributor to its quarterly performance.
Sales in the segment increased 22% at constant exchange rates to 26.15 billion Danish crowns.
The growth was driven primarily by higher treatment volumes in the United States and international markets.
Demand for obesity medicines continues to support the company’s commercial operations, with Wegovy remaining a central product in its weight-management portfolio.
The increase in sales demonstrated continued patient demand, although pricing adjustments and competitive developments remain important considerations.
Novo Nordisk has been expanding its obesity treatment business as the market for weight-management medicines develops.
The segment’s growth contributed to the company’s decision to raise its full-year financial expectations.
However, analysts noted that favourable pricing adjustments also played a role in the stronger-than-expected quarterly sales performance.
Jefferies said Novo Nordisk’s third-quarter results were stronger than expected but cautioned that part of the revenue outperformance reflected favourable gross-to-net pricing adjustments.
According to the investment firm, approximately 2 billion crowns of pricing-related benefits contributed to the reported sales beat, primarily supporting injectable Wegovy.
Gross-to-net adjustments reflect the difference between a pharmaceutical product’s gross selling price and the revenue ultimately recognised after rebates, discounts and other pricing arrangements.
Jefferies estimated that excluding the favourable pricing impact would have reduced the company’s adjusted sales beat from approximately 8% to around 5%.
The analysts also indicated that Wegovy sales would have fallen short of expectations without the pricing benefit.
The assessment suggests that while underlying demand remained strong, the headline revenue performance was partly influenced by pricing factors that may not necessarily recur at the same level.
Investors will therefore be monitoring the balance between prescription volume growth and realised selling prices in future quarters.
Jefferies indicated that Novo Nordisk’s improved full-year guidance could lead to upward revisions in market expectations.
The investment firm estimated that consensus forecasts for adjusted sales and adjusted operating profit could increase by approximately three percentage points at the midpoint.
The assessment reflects the improvement in Novo Nordisk’s guidance from a midpoint decline of 3% to approximately flat growth.
However, the analysts also highlighted uncertainties surrounding the company’s financial outlook and management changes.
“CFO change will probably raise some debate,” Jefferies analysts said.
The firm maintained its Hold rating on Novo Nordisk shares, with a price target of 275 Danish crowns.
The rating reflected a measured assessment of the company’s outlook despite the stronger quarterly results and improved annual guidance.
Novo Nordisk also increased its free cash flow expectations for 2026.
The company now forecasts free cash flow of between 60 billion and 70 billion Danish crowns, compared with its previous guidance of 45 billion to 55 billion crowns.
At the midpoint, the revised forecast implies free cash flow of approximately 65 billion crowns, representing a 15 billion crown increase from the previous midpoint.
According to Jefferies, the updated outlook also exceeds the market consensus of approximately 45 billion crowns.
The higher forecast suggests that Novo Nordisk expects stronger cash generation than previously anticipated.
Free cash flow is an important measure of a company’s ability to generate cash after accounting for capital expenditure.
For pharmaceutical companies, cash generation provides resources to support research and development, manufacturing investment and other corporate priorities.
The substantial increase in Novo Nordisk’s forecast therefore represents another positive element of its updated financial outlook.
Alongside its quarterly results, Novo Nordisk announced plans to reduce US wholesale acquisition costs for Wegovy and Ozempic from January 1, 2027.
The company intends to lower the list price of Wegovy by approximately 50% and Ozempic by around 35%.
Both products will have a wholesale acquisition cost of $675 under the planned changes.
Wegovy is used for weight management, while Ozempic is primarily prescribed for the treatment of type 2 diabetes.
The pricing reductions represent a significant change to the company’s US commercial strategy.
Lower list prices could affect reported revenue per unit, although the financial impact will also depend on rebates, discounts, reimbursement arrangements and treatment volumes.
The changes may influence access and affordability for certain patients, but the effect on individual out-of-pocket costs will vary according to insurance coverage and other factors.
Investors will be assessing how the revised pricing structure affects Novo Nordisk’s revenue and profitability in 2027.
Novo Nordisk’s stronger quarterly results come as the company continues to navigate a changing market for obesity and diabetes treatments.
The 22% increase in obesity care revenue demonstrated continued demand, while the planned US price reductions indicate that pricing will remain an important factor in future financial performance.
The company must balance growth in treatment volumes with changes in realised selling prices.
Jefferies’ comments regarding the approximately 2 billion crown gross-to-net pricing benefit highlighted the importance of distinguishing recurring demand growth from favourable accounting or pricing adjustments.
Meanwhile, the impairment charges associated with ziltivekimab and manufacturing restructuring demonstrate that development and operational decisions can have a substantial effect on reported profitability.
Despite these challenges, Novo Nordisk’s improved guidance and higher free cash flow forecast suggest stronger financial expectations for the remainder of 2026.
Novo Nordisk enters the final quarter of 2026 with an improved financial outlook following stronger-than-expected third-quarter results.
Adjusted sales reached 79.20 billion Danish crowns, exceeding analyst expectations, while adjusted operating profit increased 27% at constant exchange rates to 31.72 billion crowns.
Obesity care revenue rose 22% to 26.15 billion crowns, supported by higher treatment volumes across the United States and international markets.
The company now expects adjusted sales and adjusted operating profit to range from a 2% decline to 2% growth at constant exchange rates, improving on its previous forecast of a 6% decline to flat performance.
Free cash flow guidance was also increased to between 60 billion and 70 billion crowns.
However, reported operating profit declined following 8.7 billion crowns of non-cash impairment charges, while analysts highlighted the contribution of favourable pricing adjustments to the quarterly revenue beat.
Looking ahead, the planned reductions in US list prices for Wegovy and Ozempic from January 2027 will be an important development for the company’s commercial outlook.
Investors will be monitoring treatment volumes, pricing trends, operating profitability and the potential financial effects of the revised US pricing strategy.
The stronger third-quarter performance and improved annual guidance provide evidence of continued demand for Novo Nordisk’s medicines, although future growth will depend on the company’s ability to navigate pricing pressures and sustain its market position.
Novo Nordisk stock price
| 27 min | |
| 51 min | |
| 3 hours | |
| 3 hours | |
| 3 hours | |
| 4 hours | |
| 5 hours | |
| 6 hours | |
| 7 hours | |
| Nov-03 | |
| Nov-01 | |
| Oct-29 | |
| Oct-29 | |
| Oct-28 | |
| Oct-28 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, alerts, and much more.
Learn more about Finviz Elite